Home/Pipeline/XIFAXAN (rifaximin)

XIFAXAN (rifaximin)

Pediatric Irritable Bowel Syndrome with Diarrhea (IBS-D)

Key Facts

Indication
Pediatric Irritable Bowel Syndrome with Diarrhea (IBS-D)
Phase
Phase 3
Status
Active
Company

About Bausch Health

Bausch Health is a restructured specialty pharma company with a mission to enrich lives through better health outcomes in key therapeutic areas. Its strategy centers on acquiring and in-licensing commercial-stage assets, followed by aggressive lifecycle management to extend product value. The company has successfully separated its eye health business (Bausch + Lomb) and is now focused on core segments in GI, aesthetics, and international markets, while navigating a significant debt burden.

View full company profile

About Bausch Health

Bausch Health is a restructured specialty pharma company with a mission to enrich lives through better health outcomes in key therapeutic areas. Its strategy centers on acquiring and in-licensing commercial-stage assets, followed by aggressive lifecycle management to extend product value. The company has successfully separated its eye health business (Bausch + Lomb) and is now focused on core segments in GI, aesthetics, and international markets, while navigating a significant debt burden.

View full company profile